PureTech Health (PRTC.L) Stock Price
£138.6 3.6%
to add to portfolio
AI Score
-
Alternative
7 -
Fundamental
2 -
Technical
5
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on PureTech Health, AI stock picks, stock alerts and much more.
PRTC.L AI Stock Analysis
AI stock analysis for PRTC.L is missing at the moment.
Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like PureTech Health (PRTC.L) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.
Sign up and become a member to get access to AI stock analysis.
Sign up
PureTech Health (PRTC.L) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of PureTech Health (PRTC.L), currently trading at £138.6, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About PRTC.L
-
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States.
-
Symbol
PRTC.L
-
Market
LSE
-
Industry
Biotechnology
-
Market Cap
334.5M
Similar Stocks
 |
Codexis 0I0X.L |
$3 5.5% |
5 |
 |
Oxford Nanopore Technologies plc ONT.L |
£208.2 1.3% |
7 |
 |
Sareum Holdings SAR.L |
£22 8.3% |
4 |
 |
Viridian Therapeutics 0K1R.L |
$19.19 8.5% |
6 |
 |
Avacta Group Plc AVCT.L |
£49 1% |
4 |
News
PRTC.L Alternative Data
Web Traffic
PureTech Health receives an estimated 10565 monthly visitors to puretechhealth.com.
-
Web Traffic
10565
-
Change from Previous Month
79.7%
-
3 Month Change
135.8%
-
YoY Change
135.8%
Twitter Followers
PureTech Health has 4,301 Twitter Followers on its main Twitter (also known as X) account, which is up by 0.3% over the last month.
-
Twitter Followers
4301
-
Daily Change
0.1%
-
1 Month Change
0.3%
-
3 Month Change
0.6%
-
YoY Change
0.6%
Job Postings
PureTech Health currenly has an estimated 0 open job postings.
-
Job Postings
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
Reddit Mentions
PureTech Health has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
LinkedIn Followers
11,407 are following PureTech Health on LinkedIn, up by 1.1% over the last month.
-
LinkedIn Followers
11407
-
Daily Change
1.1%
-
1 Month Change
1.1%
-
3 Month Change
2.6%
-
YoY Change
2.6%
LinkedIn Employees
According to LinkedIn, PureTech Health has 90 employees, up by 2.3% over the last month.
-
LinkedIn Employees
90
-
Daily Change
2.3%
-
1 Month Change
2.3%
-
3 Month Change
2.3%
-
YoY Change
2.3%
Business Outlook
According to employee reviews, the business outlook among employees at PureTech Health is 50 out of 100 (neutral).
-
Business Outlook
50
-
Change from Previous Month
0%
-
3 Month Change
0%
-
YoY Change
0%
News Mentions
PureTech Health was mentioned 0 times in the news yesterday.
-
News Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
PRTC.L Financials
PRTC.L Key Metrics
-
Total Revenue
$4M
-
Net Income
$95.3M
-
Earnings per Share
$0.15
-
Free cash flow
-$54.4M
-
EBITDA
$102M
-
EBITDA Ratio
8.66327
-
Total Assets
$602.6M
PRTC.L 2-year Revenue & Income
PRTC.L 2-year Free Cash Flow
PRTC.L Technicals
PRTC.L SMA
PRTC.L RSI
FAQ
What's the current price of PureTech Health (PRTC.L) Stock?
The price of an PureTech Health (PRTC.L) share is £138.6.
What's the market cap of PureTech Health?
The current market cap of PureTech Health is 334.5M.
Should I buy or sell PRTC.L?
PureTech Health shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, PureTech Health is better viewed as a hold or accumulate position while waiting for further developments.
Is PureTech Health a good investment?
The current analysis of PureTech Health's fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in PureTech Health's portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.
Is now a good time to buy PureTech Health (PRTC.L) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for PureTech Health stock is currently neutral, suggesting a cautious approach might be wise.
What are some stocks similar to PureTech Health (PRTC.L) that investors often compare it to?
PureTech Health (PRTC.L) is often compared to similar stocks such as Codexis, Oxford Nanopore Technologies plc, Sareum Holdings, Viridian Therapeutics and Avacta Group Plc.
What is the forecast for PureTech Health's stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast PureTech Health's stock price to be around £140.7 in 2026. Starting from the current price of £138.6, this represents a 1.5% change in price, indicating a neutral outlook for the stock.
How to buy PureTech Health (PRTC.L) Stock?
PureTech Health stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy PureTech Health shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.